87 results about "High glucose" patented technology

The invention relates to the technical field of biological pharmacy, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell inflammation. The recombinant protein DEL-1 has a remarkable inhibition effect on pancreatic beta cell inflammatory response induced by high glucose and high fat. Experiments show that in an islet beta cell inflammation model constructed by combining high glucose with palmitic acid, DEL-1 can significantly reduce the expression level of inflammatory factors such as IL-1beta, IL-6, TNF-alpha and the like. The DEL-1 is proved to have a definite effect of resisting pancreatic beta cell inflammation.

The application discloses a kind of glucose oxidase sensors based on modified multi-walled carbon nanotube modification, it is related to glucose oxidase sensor technical field, including the following steps: (1) modified multi-walled carbon nanotube preparation;(2) glassy carbon electrode is carried out surface polishing treatment;(3) obtain modified multi-walled carbon nanotube dispersion;(4) obtain glucose oxidase liquid;(5) glucose glucose oxidase liquid impregnation electrode;(6) using Nafion solution covers electrode;The sensor obtained after the electrode is modified by introducing modified multi-walled carbon nanotube in the application, not only has higher glucose detection sensitivity, but also has excellent stability.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

An auricular stimulation device having surface electrodes biased towards each other, and offset from one another, is provided. The stimulation device can be positioned about the ear of a patient with each of the electrodes overlaying auricular ear tissue containing innervation supplied by an auricular branch of the vagus nerve. The electrodes transcutaneously stimulate the auricular branch. Also provided is a method of treating a patient using the auricular stimulation device. The stimulation device can be used for treating patients with conditions such as high blood pressure, depression, high blood glucose level, and tinnitus. Also provided is a diagnostic and therapeutic system having the auricular stimulation device, a smart device and a monitoring device. The smart device controls the auricular stimulation device based on biomarker information received from the monitoring device; and on information related to the patient, such as age, musculoskeletal stability, etc.; and / or on user input.

The present invention relates to a biocompatible tattoo ink that changes color in response to varying glucose levels in the bloodstream, providing a continuous monitoring method for individuals with diabetes. The ink contains glucose-sensitive agents that cause the tattoo to change from green (normal glucose levels) to red (high glucose levels) or blue (low glucose levels). Additionally, the ink shifts back to green when blood glucose returns to normal from either hyperglycemia or hypoglycemia. This provides a real-time visual indicator of glucose levels and enables users to monitor their health without additional equipment.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

The application discloses a kind of recombinant escherichia coli for producing L-tyrosine and application, belong to genetic engineering and bioengineering technical field.The application knocks out aroP and tyrP gene, expresses the yddG gene of escherichia coli endogenous to modify the aromatic amino acid transport system of escherichia coli, then heterologous expression comes from bifidobacterium fpk and expresses the ppsA and tktA gene of escherichia coli endogenous to increase the precursor supply of shikimic acid pathway, again through the anti feedback gene expression aroG and tyrA 3-deoxy-D-arabino-heptulosonic acid-7-phosphate synthetase, branch acid mutase and prephenate dehydrogenase are removed feedback inhibition, increase the carbon flux of shikimic acid pathway.Knock out tyrR gene removes the repression of TyrR protein to shikimic acid pathway key enzyme, again knock out trpE and pheA gene to block partial side reaction of shikimic acid pathway, so that the synthesis flux of L-tyrosine increases.Finally knock out endogenous poxB gene to realize the modification of acetic acid pathway, realizes the stable fermentation performance of high glucose concentration.

The application provides application of circ-0007527 as a target in screening of drugs for treating peritoneal dialysis related peritoneal fibrosis. The application also provides application of an inhibitor of circ-0007527 in preparation of a drug for treating peritoneal dialysis related peritoneal fibrosis. In a mouse peritoneal fibrosis model induced by high glucose peritoneal dialysis solution, circRNA expressed in peritoneal tissues is screened, and after bioinformatics analysis, it is found that the differential expression amount of circ-0007527 in the fibrotic peritoneal tissue is the highest, and the high expression of circ-0007527 in the fibrotic peritoneal tissue is verified by real-time fluorescent quantitative PCR. Further in-vitro cell experiments find that down-regulation of the expression of circ-0007527 can significantly inhibit peritoneal mesothelial cell phenotype transformation, proliferation and apoptosis, and thus reduce peritoneal injury and delay peritoneal fibrosis progression.

This invention provides the application of glucose-responsive nanohydrogels in the preparation of drugs for treating skin injuries. The method includes the following steps: mixing hyaluronic acid with a phenylboronic acid compound, adding 3-aminophenylboronic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide, and performing a grafting reaction to obtain boric acid-modified hyaluronic acid; adding myricetin-3-O-galactoside, phospholipids, and cholesterol to an organic solvent, followed by thin-film hydration and ultrasonic treatment to obtain nanoliposomes; mixing the boric acid-modified hyaluronic acid with a polyvinyl alcohol solution, then adding the nanoliposome solution, and finally mixing to obtain the resulting nanohydrogel. The glucose-responsive nanohydrogel of this invention achieves adaptive drug release in the high glucose environment of diabetic wounds and regulates local metabolic homeostasis of the wound, especially the lysine degradation pathway in amino acid metabolism.

The invention belongs to the field of blood glucose detection, and relates to a high-sensitivity blood glucose noninvasive detection method and system based on polarized terahertz photoacoustic, which combines the advantages of terahertz wave band detection and photoacoustic detection, fully utilizes the chiral characteristics of glucose molecules, and adopts polarized terahertz photoacoustic to detect the blood glucose concentration. Polarization optical rotation change information is extracted through the time domain photoacoustic signal; by selecting the characteristic absorption wave band of glucose and utilizing the difference between glucose and other blood components in chiral characteristics, the influence of water and other high-concentration ions on terahertz signals is remarkably reduced, so that the selectivity and the anti-interference capability of blood glucose detection are effectively improved; terahertz non-ionizing radiation is adopted as an excitation source, no ionizing injury risk is caused to a human body, and the device is suitable for long-term repeated detection and is expected to be popularized and applied in wearable or bedside monitoring equipment.

Disclosed is a blood glucose measurement device capable of improving blood glucose measurement accuracy by focusing rays of light for blood glucose measurement in the measurement area of an object. According to an embodiment of the present invention, the blood glucose measurement device comprises: a light source unit disposed to output a plurality of first light rays for measuring blood glucose in the measurement area of an object; an optical unit including one or more optical bodies disposed to emit a plurality of first light rays toward the measurement area of the object; and a light-receiving unit disposed to receive a plurality of second light rays output through an interaction between the plurality of first light rays and the object. The one or more optical bodies include: a plurality of lenses arranged to condense a plurality of first light rays on the first surface of one or more optical bodies facing the light source unit; a reflective surface arranged to reflect a plurality of first light rays condensed by the plurality of lenses on the second surface of one or more optical bodies; and a refractive surface arranged to refract a plurality of first light rays reflected at the reflective surface toward the measurement area of the object on the third surface of one or more optical bodies.

The present application provides a Pichia pastoris engineering bacterium and a kit and application thereof, a method for obtaining the Pichia pastoris engineering bacterium, a method for improving glucose oxidase yield of the Pichia pastoris, and a method for producing glucose oxidase, wherein the Pichia pastoris engineering bacterium carries a glucose oxidase gene and a pyruvate kinase gene. The Pichia pastoris engineering bacterium of the present application can realize high glucose oxidase yield and high enzyme activity, and lays a good foundation for large-scale production of glucose oxidase.

The invention relates to the technical field of biology, in particular to application of SAFit2 in preparation of a reagent for improving pancreas islet dysfunction. The invention discovers that SAFit2 has a remarkable improvement effect on insulin secretion dysfunction in a high-glucose and high-fat induced islet injury model. Experiments show that in a high glucose (33 mM) combined palmitic acid (500 [mu] M) injury model, the SAFit2 can significantly improve the insulin secretion function of the pancreas islet. Specifically, the SAFit2 is pretreated, the glucose stimulated insulin secretion (GSIS) index of the pancreas islet and the intracellular insulin content are remarkably increased, insulin secretion under high glucose stimulation is promoted, and the SAFit2 is proved to have the effect of promoting the insulin secretion function of the pancreas islet beta cells.

The invention relates to a polarization spectrum device, in particular to an integrated polarization spectrum device for noninvasive blood glucose measurement and a blood glucose measurement method, and solves the technical problem of low blood glucose measurement precision caused by the problems of low optical parameter dimension, complex algorithm processing, overfitting and the like of the existing noninvasive blood glucose measurement device. According to the integrated polarization spectrum device for noninvasive blood glucose measurement, polarization signals and multispectral signals are obtained through the polarization path and the spectrum path respectively, compared with a traditional blood glucose measurement method, the optical information dimension of the integrated polarization spectrum device is effectively improved, efficient complementation of spectrum information and polarization information can be achieved, and therefore the blood glucose measurement precision is improved. The invention further provides a blood glucose measurement method, the LSTM neural network is adopted for blood glucose prediction, the problem of overfitting of high-dimensional polarization spectrum information by a traditional BP neural network can be avoided, and the blood glucose prediction precision is improved.

The application provides application of a TAS2R4 agonist in preparation of a drug for treating and preventing diabetic nephropathy, and comprises that a bitter taste receptor 4 subtype (TAS2R4) can be used as a drug target point for treating and preventing diabetic nephropathy, and quinine is used as a TAS2R4 agonist. Specifically, mouse diabetic nephropathy induced by a chemical reagent and mouse podocyte cell line MPC cell damage caused by chronic high glucose are taken as research objects, it is found that mouse TAS2R4 agonist quinine has a prevention and treatment effect on diabetic nephropathy, has a protection effect on podocyte loss caused by high glucose, and has an activation effect on mouse kidney TAS2R4 molecular signal, and a possible molecular mechanism is discussed from the aspects of inhibiting NLRP3 inflammasome activation and NF-kappa B signal activation path, and theoretical basis and technical support are provided for prevention and treatment of diabetic nephropathy, other kidney diseases with inactivation of TAS2R4 molecular signal and other diseases by using TAS2R4 agonists including quinine.

The invention relates to the field of biological medicine and ophthalmic diseases, in particular to a target protein inhibitor for preventing and treating proliferative diabetic retinopathy and a screening method and application of the target protein inhibitor. The screening method comprises the following steps: 1) obtaining a three-dimensional crystal structure of CTSH; 2) constructing a binding pocket at an active site; 3) performing molecular docking and scoring on the small molecule library, and screening candidate compounds with binding energy lower than a preset threshold value; and 4) performing molecular dynamics simulation on the candidate compound and the CTSH compound, and selecting a compound with a stable structure and low binding free energy as an inhibitor. The inhibitor obtained by screening comprises eriodictyin, polygala tenuifolia sucrose ester B or an AP-III-a4 inhibitor. Genetic causal inference proves that CTSH has a causal driving effect on PDR, inflammation and pathological angiogenesis can be remarkably inhibited by regulating CTSH expression under a high glucose condition, and effective inhibitor components are finally screened.

The application provides a low-gluten high-dietary fiber excellent flavor rice as well as a breeding method and application thereof, and relates to the technical field of rice breeding. The breeding method uses a high-dietary fiber rice variety as a female parent and a low-gluten flavor rice variety as a male parent to perform hybridization, and then performs genotype detection on the F2 generation by using Badh-M2 and Lgc1 molecular markers respectively, and combines with agronomic trait selection to realize efficient polymerization of three functional genes of flavor, low gluten and high dietary fiber. The method significantly improves the selection efficiency, avoids trait loss and cycle extension caused by multiple backcrossing. The bred rice has the effects of rich flavor, significantly reduced rice gluten content, obviously increased dietary fiber content and reduced blood glucose generation index, and meanwhile, maintains the effects of high yield, early maturity, excellent plant leaf morphology and good ecological adaptability, and can meet the nutritional needs of chronic kidney disease, diabetes and obese people for functional staple food.

The application belongs to the technical field of antibacterial infection materials, and particularly relates to preparation and application of a biomimetic mineralization nanoparticle. x S y / AZM, which is obtained by fixing glucose oxidase (GOx) in FexSy nanoparticles hybridized with azithromycin (AZM) through a biomimetic mineralization strategy, and the nanoparticle GOx@Fe x S y / AZM serves as a therapeutic drug to catalyze a large amount of active oxygen free radicals (ROS) to improve inflammatory response in order to rapidly kill infectious microorganisms in the early stage of bacterial infection of a wound surface; and in the subsequent healing period, H2S released by the material and AZM will jointly promote the polarization of macrophages to M2 macrophages of a repair type to effectively mediate the tissue repair after a high inflammatory response, so that the ordered treatment of a high blood sugar infection wound surface is achieved.

The invention belongs to the technical field of biological medicines, and discloses 5-(benzyl carbamoyl)-indole compounds and application thereof in preparation of medicines for preventing and / or treating diabetic cardiomyopathy. In-vivo and in-vitro experiments prove that the 5-(benzyl carbamoyl)-indole compound disclosed by the invention can effectively reduce blood sugar and improve myocardial cell injury induced by high glucose and high fat, does not cause body weight increase, has a remarkable curative effect of improving diabetic cardiomyopathy, is small in side effect, and can be used for preparing medicines for treating diabetic cardiomyopathy. And the pharmaceutical composition has a remarkable effect at a low dosage, has a more excellent effect compared with a high-dosage positive drug, and provides a new drug for treating diabetic cardiomyopathy, so that the pharmaceutical composition has a wide application prospect.

The application provides a self-powered and biological oxygen supply synergistic composite microneedle dressing and a preparation method and application thereof. The microneedle dressing is prepared by the following steps: taking methacrylated gelatin as a base, loading dopamine modified poly 3,4-ethylenedioxythiophene conductive particles on the needle tip, loading ZIF-90 wrapped glucose oxidase on half of the needle tip, loading ZIF-90 wrapped horseradish peroxidase particles on the other half of the needle tip, adding chlorella to the backing layer, and preparing the dressing through micro-molding and ultraviolet light crosslinking. The composite microneedle dressing prepared by the application can realize self-powered electric stimulation, in-situ hypoglycemia, biological oxygen supply, broad-spectrum antibiosis, antioxidant multiple functions simultaneously, precisely targets the pathological characteristics of high glucose, hypoxia, susceptibility to infection and slow healing of diabetic wounds, significantly accelerates wound healing and tissue regeneration, and provides a minimally invasive, efficient and safe new treatment strategy for diabetic chronic wounds.

The application belongs to the technical field of food and medicine, and particularly relates to a cordyceps militaris polysaccharide, a preparation method and application thereof. The application provides a method for improving the yield of cordyceps militaris polysaccharide by optimizing a liquid fermentation process, and proves that the cordyceps militaris polysaccharide has a good blood glucose lowering effect on T2DM mice. The application provides a liquid fermentation method capable of significantly improving the yield of cordyceps militaris polysaccharide, and the yield of the cordyceps militaris polysaccharide is improved to 82.7 mg / g mycelium, and the culture time is short. The cordyceps militaris polysaccharide obtained has a clear key structure characteristic range. The cordyceps militaris polysaccharide obtained has a good blood glucose lowering effect on T2DM mice, and by remodeling the intestinal flora, improving the SCFAs level, and improving a plurality of high blood glucose related indexes, the T2DM related high blood glucose symptoms are relieved.

The invention discloses application of polypeptide in preparation of a diabetic nephropathy alleviator, and belongs to the technical field of medicines. The cordyceps sinensis beta-tubulin polypeptide is synthesized by analyzing the structure of the cordyceps sinensis beta-tubulin and selecting amino acid peptide fragments from the 84th site to the 107th site. The apoptosis of the glomerular mesangial cells is induced by using 50 mmol / L of glucose, and meanwhile, the apoptosis of the glomerular mesangial cells induced by high glucose can be relieved by adding the cordyceps sinensis beta-tubulin polypeptide. A treatment test of the cordyceps sinensis beta-tubulin polypeptide on diabetic nephropathy model mice shows that the body mass and fasting blood-glucose levels of the mice in the cordyceps sinensis beta-tubulin polypeptide group are remarkably reduced, the 24-hour urine protein content of the mice is remarkably reduced, and the kidney injury of the mice in the cordyceps sinensis beta-tubulin polypeptide group is remarkably relieved.

The present application discloses a phenyl boronic acid compound, which contains a phenyl boronic acid group and a carbon-carbon double bond group, and the phenyl boronic acid group can be combined with glucose. The present application also discloses a polymer, which is obtained by free radical copolymerization of the above-mentioned phenyl boronic acid compound, a monomer containing A and an initiator in a solvent. The present application further discloses an insulin sustained-release preparation containing the above-mentioned polymer, which has different insulin release rates under different glucose concentrations, and can accelerate the release of insulin under a hyperglycemic environment to reduce blood glucose. The present application further discloses a preparation method of the above-mentioned insulin sustained-release preparation, which self-assembles the negatively charged insulin and the positively charged double-phenyl boronic acid modified polymer into the insulin sustained-release preparation through electrostatic interaction, and has the characteristics of high loading rate. The prepared insulin sustained-release preparation can release insulin, and the released insulin can bind to insulin receptors in the body to reduce blood glucose level.

The invention relates to the technical field of sustained-release preparations, and discloses a hydrogel dressing based on a sugar response sustained-release drug as well as a preparation method and application of the hydrogel dressing. HA-PBA is used as a first network to provide sugar responsiveness and biological activity, PVA is used as a second network to enhance mechanical strength and moisture retention, HA-PBA and PVA form boric acid ester bonds under the alkaline condition of 7.2-9.0, a double-network structure is formed through interaction of the boric acid ester bonds and hydrogen bonds, and the hydrogel is obtained. The hydrogel formed by the invention can be endowed with self-healing and shear thinning characteristics, and the shear thinning characteristic enables the hydrogel to have injectability, so that the hydrogel is suitable for minimally invasive implantation; and the self-healing capability ensures that the dressing recovers integrity after the wound surface deforms. When the hydrogel is used for treating chronic diabetic wounds, borate bonds are dissociated under high glucose concentration, so that the degradation of the hydrogel network is accelerated, the functional protein medicine is released to realize treatment, and the treatment accuracy is improved.

The invention discloses application of an AMSCs-derived exosome in preparation of a medicine for treating diabetic vasculopathy, and relates to the technical field of medicines. The exosome is separated and extracted from the AMSCs, the HUVECs under the high glucose condition are intervened, it is proved for the first time that the exosome derived from the AMSCs can improve the HUVECs autophagy obstacle induced by the high glucose, it is also proved that the exosome derived from the AMSCs can weaken the activation effect of the high glucose on AKT / mTOR, meanwhile, an AKT / mTOR signaling pathway activator MHY1485 can block the activation of the exosome on the HUVECs autophagy, and therefore the HUVECs autophagy obstacle induced by the high glucose is inhibited. It is prompted that the exosome derived from the AMSCs and the AKT / mTOR signal channel inhibitor have a certain curative effect on the vascular endothelial cell autophagy disorder related diseases.

The invention discloses a high-sensitivity analysis method for rapidly detecting lipid droplets, and a probe has high sensitivity, good light stability and low cytotoxicity and can specifically target the lipid droplets in cells. The probe provided by the invention can be used for monitoring accumulation and viscosity change of lipid droplets in living cells, and is especially suitable for real-time monitoring of the dynamic process of the lipid droplets in the living cells under stimulation of oleic acid, lipopolysaccharide, high glucose and the like; and a potential tool is provided for life science research, drug screening and development, disease diagnosis and pathology research.

A baked dough food for consumption during fasting, methods of making the same, and methods of fasting that include consumption of the baked dough food are disclosed herein. The baked dough food includes a dry ingredient selected from the group consisting of almond flour, coconut flour, Psyllium husk powder, chia powder, flaxseed powder, and combinations thereof, baking soda, at least one of clarified butter, an oil, cacao butter, almond butter, peanut butter, unsweetened almond milk, or water, a sweetener, and a flavoring agent. The baked dough food does not produce an insulin spike or increased blood glucose level upon consumption.

The invention relates to a combined treatment method for tumors in a diabetic state, and belongs to the field of biological medicines. According to the method, photodynamic therapy is carried out by adopting photosensitive composite nanoparticles (UCS NPs) constructed by upconversion nanoparticles-silicon dioxide-chlorin e6, and an inhibitor for inducing a metastasis pathway by aiming at tumor-related fibroblasts is used in a combined manner. Active oxygen free radicals are generated through photodynamic therapy to kill tumor cells, and an inhibitor is combined to block a metastasis pathway, so that tumor growth and metastasis are synergistically inhibited in a diabetes mellitus high-glucose microenvironment. The problem that the curative effect of a single therapy is limited under the complex state of diabetes mellitus is solved, and the pharmaceutical composition has the advantages of strong synergistic effect, high targeting property, good biological safety and the like, is suitable for treating diabetes mellitus complicated with melanoma, and has a wide clinical application prospect.

Disclosed herein is a method for promoting insulin sensitivity in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising an monocarboxylate transporter 1 (MCT1) inhibitor. For example, the subject can have or be at risk of developing a metabolic disorder characterized by high blood glucose and low insulin levels, e.g., type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and atherosclerosis. The subject can also have been diagnosed with cancer cachexia or with a cancer, such as a solid tumor or lymphoma.